Bristol-Myers Squibb buys Celgene
The drugmaker merger is worth $74 billion.
Drugmaker Bristol-Myers has bought biotech company Celgene in a blockbuster $74 billion deal. The merger is the largest in the history of pharmaceuticals. The purchase has led to a surge in shares in both corporations.
Why Bristol- Myers bought Celgene
Bristol-Myers is the most dominant drugmaker in the US, but has faced competition from other pharmaceutical corporations like Merck in cancer fighting medication. Celgene is a biotech company that is working on gene therapy this is supposed to attack cancer cells. The merger is supposed to help the companies work together to create groundbreaking treatment for life-threatening illnesses. Bristol-Myers chief executive officer(CEO), Giovanni Cafario, noted the importance of the merger in a statement.
‘Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,’ noted Cafario.
‘Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,’ noted Cafario.
The merger will greatly benefit Celgene because its stock had been suffering in 2018. The company’s shares fell 40% even after billion-dollar purchases of other biotech corporations. Bristol-Myers stock suffered last year when the US Food and Drug Administration (FDA) delayed approval of two of its medications. Brad Loncar, chief executive officer(CEO) of Loncar Investments, noted that the joint venture was necessary for both companies to overcome poor business decisions.
‘Both of them were coming into this year kind of limping. Merging together makes the combined entity a lot stronger,’ said Loncar.
Details of the merger
Under the deal, Celgene shareholders will get $102.43 per Bristol-Myers share. They will also own 31% of the company, while Bristol-Myers stock purchasers will have control of 69% of the combined corporation. The merger is expected to be completed by the third quarter (Q3) of2019.
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Be ready to act on ECB opportunities
Learn how the ECB’s monetary policy announcements affect interest rates and price stability ahead of its next meeting in 30 January 2025.
- How might the next meeting affect the markets?
- What are the key rate decisions to watch?
- Why is the Governing Council announcement important for traders?
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
